The price of Clover Health Investments Corp (NASDAQ: CLOV) closed at $0.78 in the last session, down -1.79% from day before closing price of $0.80. In other words, the price has decreased by -$0.0143 from its previous closing price. On the day, 11921478 shares were traded.
Ratios:
We take a closer look at CLOV’s different ratios to gain a better understanding of the stock. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cowen on February 02, 2022, Upgraded its rating to Market Perform and sets its target price to $3 from $7 previously.
On February 02, 2022, Canaccord Genuity started tracking the stock assigning a Buy rating and target price of $6.
On January 19, 2022, SVB Leerink started tracking the stock assigning a Mkt Perform rating and target price of $3.SVB Leerink initiated its Mkt Perform rating on January 19, 2022, with a $3 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 14 ’24 when Loengard Anna U bought 137,000 shares for $0.73 per share. The transaction valued at 100,010 led to the insider holds 538,841 shares of the business.
Loengard Anna U bought 13,625 shares of CLOV for $9,946 on Mar 14 ’24. The Director now owns 15,125 shares after completing the transaction at $0.73 per share. On Sep 06 ’23, another insider, Loengard Anna U, who serves as the Director of the company, bought 11,000 shares for $1.30 each. As a result, the insider paid 14,300 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLOV now has a Market Capitalization of 387.91M and an Enterprise Value of 149.89M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.19 while its Price-to-Book (P/B) ratio in mrq is 1.32. Its current Enterprise Value per Revenue stands at 0.07 whereas that against EBITDA is -0.71.
Stock Price History:
Over the past 52 weeks, CLOV has reached a high of $1.63, while it has fallen to a 52-week low of $0.71. The 50-Day Moving Average of the stock is 0.9227, while the 200-Day Moving Average is calculated to be 1.0258.
Shares Statistics:
According to the various share statistics, CLOV traded on average about 9.57M shares per day over the past 3-months and 18.69M shares per day over the past 10 days. A total of 393.27M shares are outstanding, with a floating share count of 369.53M. Insiders hold about 24.22% of the company’s shares, while institutions hold 19.87% stake in the company. Shares short for CLOV as of Feb 29, 2024 were 36.54M with a Short Ratio of 3.82, compared to 27.68M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.49% and a Short% of Float of 9.20%.
Earnings Estimates
The company has 3 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.08 for the current quarter, with a high estimate of -$0.06 and a low estimate of -$0.09, while EPS last year was -$0.15. The consensus estimate for the next quarter is -$0.03, with high estimates of $0 and low estimates of -$0.06.
Analysts are recommending an EPS of between -$0.1 and -$0.27 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.15, with 3 analysts recommending between -$0.02 and -$0.25.
Revenue Estimates
According to 4 analysts, the current quarter’s revenue is expected to be $401.72M. It ranges from a high estimate of $545.02M to a low estimate of $321.98M. As of the current estimate, Clover Health Investments Corp’s year-ago sales were $527.77M, an estimated decrease of -23.90% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $392.41M, a decrease of -23.60% over than the figure of -$23.90% in the same quarter last year. There is a high estimate of $514.38M for the next quarter, whereas the lowest estimate is $323.39M.
A total of 4 analysts have provided revenue estimates for CLOV’s current fiscal year. The highest revenue estimate was $2.06B, while the lowest revenue estimate was $1.28B, resulting in an average revenue estimate of $1.56B. In the same quarter a year ago, actual revenue was $2.03B, down -23.30% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $1.63B in the next fiscal year. The high estimate is $2.22B and the low estimate is $1.36B. The average revenue growth estimate for next year is up 4.30% from the average revenue estimate for this year.
